New imaging tracer could spot tumors more clearly

NCT ID NCT07258836

Recruiting now Diagnosis Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jan 06, 2026 · Last updated May 20, 2026 · Updated 18 times

Summary

This study tests a new injection called [18F]LY4214835 to see if it is safe and how it spreads in the body. It includes both healthy volunteers and people with cancer. The goal is to improve cancer imaging, not to treat the disease. Participation lasts about 35 days.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

BAMF Health Inc.
NOT_YET_RECRUITING

Grand Rapids, Michigan, 49503, United States
Boston Medical Center
NOT_YET_RECRUITING

Boston, Massachusetts, 02118, United States
Ichor Research
NOT_YET_RECRUITING

Syracuse, New York, 13210, United States
Invicro
RECRUITING

New Haven, Connecticut, 06510, United States
Massachusetts General Hospital (MGH)
NOT_YET_RECRUITING

Charlestown, Massachusetts, 02129, United States
Memorial Sloan Kettering Cancer Center
NOT_YET_RECRUITING

New York, New York, 10065, United States

Conditions

Explore the condition pages connected to this study.

HEALTHY NEOPLASMS NEOPLASMS